Alpha LIduronidase IDUA or EC 184.108.40.206 Pipeline Review, H2 2017
According to the recently published report Alpha LIduronidase IDUA or EC 220.127.116.11 Pipeline Review, H2 2017; Alpha LIduronidase IDUA or EC 18.104.22.168 pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Alpha LIduronidase IDUA or EC 22.214.171.124 Alpha Liduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alphaLiduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I MPS I.
The report Alpha LIduronidase IDUA or EC 126.96.36.199 Pipeline Review, H2 2017 outlays comprehensive information on the Alpha LIduronidase IDUA or EC 188.8.131.52 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Alpha LIduronidase IDUA or EC 184.108.40.206 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I MPS I Hurler Syndrome .
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Alpha LIduronidase IDUA or EC 220.127.116.11
The report reviews Alpha LIduronidase IDUA or EC 18.104.22.168 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Alpha LIduronidase IDUA or EC 22.214.171.124 targeted therapeutics and enlists all their major and minor projects
The report assesses Alpha LIduronidase IDUA or EC 126.96.36.199 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Alpha LIduronidase IDUA or EC 188.8.131.52 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Alpha LIduronidase IDUA or EC 184.108.40.206
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and itâs most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Alpha LIduronidase IDUA or EC 220.127.116.11 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope